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Background: High serum Retinol Binding Protein 4 (RBP4) levels were associated with insulin-resistant states in
humans. To determine which fat compartments are associated with elevated RBP4 levels in humans, we measured
serum RBP4 and hepatic fat content (HFC), visceral (VFA) and subcutaneous abdominal fat area (SFA) in 106 subjects
with non-alcoholic fatty liver disease (NAFLD) without known diabetes.
Methods: 106 patients with NAFLD (M/F: 61/45, aged 47.44 ± 14.16 years) were enrolled. Subjects with known
diabetes, chronic virus hepatitis, and those with alcohol consumption ≥30 g/d in man and ≥20 g/d in woman
were excluded. Anthropometrics and laboratory tests, including lipid profile, alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and γ-glutamyltransferase (γ-GT) were conducted. HFC, VFA and SFA were
determined by CT scan. Serum RBP4 was detected by an enzyme immunoassay kit and validated by quantitative
Western blotting.
Results: Circulating RBP4 was negatively associated with high-density lipoprotein cholesterol (HDL-c) (r = −0.392,
p < 0.001), but positively with waist-to-hip ratio (WHR) (r = 0.343, p = 0.001), triglyceride (r = 0.330, p = 0.002), VFA
(r = 0.298, p = 0.027), systolic blood pressure (r = 0.247, p = 0.020), diastolic blood pressure (r = 0.241, p = 0.023), γ-GT
(r = 0.239, p = 0.034), waist circumference (r = 0.218, p = 0.040). Differently, serum RBP4 levels were not associated
with HFC (r = 0.199, p = 0.071), SFA, age, BMI, total cholesterol, low-density lipoprotein cholesterol (LDL-c), ALT or
AST (all p > 0.05). Multiple linear regression analysis revealed that RBP4 correlated independently with VFA (Standard
β = 0.357, p = 0.019) and HDL-c (Standard β = −0.345, p = 0.023) in all subjects, HDL-c (Standard β = −0.315, p = 0.040)
in men, VFA/SFA in women (Standard β = 0.471, p = 0.049), not with HFC. However, serum RBP4 was positively
correlated with HFC when HFC below 6.34% (r = 0.574, p = 0.001).
Conclusions: RBP4 could be a marker of abdominal obesity, however, the role of RBP4 in the pathogenesis of
NAFLD is not sufficiently elucidated.
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Retinol binding protein 4(RBP4) is a 21 kDa secreted
protein that is the sole specific transport protein for
vitamin A (retinol) in blood [1]. RBP4 belongs to the
lipocalin family of proteins that transport small hydro-
phobic molecules [2]. The RBP4 gene is located on
chromosome 10 (10q23–q24) near the region that has
been linked to increased fasting glucose levels in Euro-
pean Caucasians and to type 2 diabetes in Mexican–
Americans [3,4]. Liver has the highest expression level of
RBP4; however, adipose tissue has the second highest
rate of expression [5]. In adipose tissue, RBP4 expressed
predominately in mature, lipid-laden adipocytes [6].
Studies in mice suggest that elevated serum RBP4
could play a causal role in insulin resistance. Increasing
serum RBP4 concentrations causes insulin resistance, by
transgenic overexpression or by injection of purified
RBP4 protein into wild-type mice [7]. Conversely, RBP4
knockout mice exhibit enhanced insulin sensitivity [7].
Serum RBP4 concentrations are also elevated in insulin-
resistant humans, including those who suffer from obesity,
impaired glucose metabolism [7-9]. A number of studies
in humans show that serum RBP4 levels correlate in-
versely with insulin sensitivity and/or positively with many
other components of the metabolic syndrome [8,10-17].
Improving insulin sensitivity by interventions such as life-
style modification, insulin-sensitizing drug rosiglitazone or
gastric banding surgery, is associated with lowering of
serum RBP4 in humans [8,13,14,17].
Abdominal obesity is one of the main characteristics
of the insulin resistance. Some studies have observed the
relationship between RBP4 and abdominal obesity and
found that serum RBP4 concentrations in humans cor-
relate highly with waist-to-hip circumference ratio [8],
waist circumference [11], and percent trunk fat [15].
Nora Kloting [18] found that serum RBP4 correlated
positively with adiposeRBP4 mRNA and intra-abdominal
fat mass and inversely with insulin sensitivity, independ-
ently of age, gender, and body mass index. Therefore,
visceral fat may be a major source of RBP4 in insulin-
resistant states.
So, we speculate that nonalcoholic fatty liver disease
(NAFLD), a typical case of visceral obesity, is associate
more closely with RBP4. However, research conclusions
about the relationship of RBP4 and hepatic fat content
are controversial. Some researches indicated that RBP4
is elevated in non-diabetic NAFLD patients [9], or dia-
betic NAFLD [19] or morbidly obese women, specific-
ally, in morbidly obese subjects with NAFLD [20], and
selected studies claimed that there exists a positive asso-
ciation between RBP4 and liver enzymes, specifically
ALT and GGT [9].Circulating RBP-4 correlated posi-
tively with liver fat which may reflect its effects on hep-
atic insulin sensitivity [21]. In contrast, some researchesdemonstrated that serum RBP4 is not a predictive factor
in NAFLD [22], and RBP4 did not differ among NAFLD
histological groups and thus did not identify non-
alcoholic steatohepatitis (NASH), the advanced stage of
NAFLD [23], another study showed that in NAFLD pa-
tients, serum RBP4 was significantly lower as compared
with controls and did not correlate with insulin resistance
[24]. Up to now, the relationship of RBP4 and hepatic fat
content (HFC) is still controversial, and the relevant data
of Chinese is blank.
Thus, the aim of this paper was to investigate the asso-
ciation between serum RBP4 levels and HFC, visceral
(VFA) and subcutaneous abdominal fat area (SFA), as well
as other metabolic parameters in Chinese subjects with
nonalcoholic fatty liver disease without known diabetes.
Results
The general characteristics of the subjects
HFC of all the subjects determined by CT scan varied
from 0.56% to 24.7% with a mean and standardized devi-
ation of 7.9% and 6.9%, respectively. By dividing the dis-
tribution of HFC into quartile, we found that there were
more women subjects than men subjects in groups with
lower HFC (Q1), but in groups with higher HFC (from
Q2 to Q4) there were more men subjects (Table 1).
Accompanied with the increase of HFC, BMI, waist
circumference, WHR, systolic blood Pressure (SBP), dia-
stolic blood pressure (DBP), triglyceride (TG), alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
γ-glutamyltransferase (γ-GT), VFA and SFA elevated grad-
ually, high-density lipoprotein cholesterol (HDL-c)fell grad-
ually (both p < 0.05). The four groups did not differ in
some metabolic parameters, including age, total choles-
terol (TC), low-density lipoprotein cholesterol (LDL-c),
alkaline phosphatase (ALP). No significant differ were
found in some metabolic parameters in the four groups,
including age, total cholesterol (TC),low-density lipo-
protein cholesterol (LDL-c), alkaline phosphatase
(ALP).
Serum RBP4 and VFA, SFA and other metabolic parameters
In all the subjects, serum RBP4 levels were significantly
associated with sex, weight, waist circumference, WHR,
SBP, DBP, TG, HDL-c, γ-GT, VFA, VFA/SFA, but not as-
sociated with age, BMI, TC, LDL-c, ALT, AST, and ALP
(Table 2). Considering RBP4 is sex related, we did the
correlation analysis respectively according to gender. In
women, serum RBP4 level was only significantly associ-
ated with VFA/SFA, but not associated with HFC, BMI,
liver enzymes and the other variables mentioned above.
While in men, serum RBP4 level was significantly associ-
ated with HDL-c, ALT, AST, but not associated with
HFC, VFA, SFA, BMI and the other variables mentioned
above (Table 2).
Table 1 Clinical and laboratory features of the subjects
Liver fat content (HFC) Q1 HFC < 3.26%
(n = 26)
Q2 HFC: 3.26% ~ 6.33%
(n = 27)





Sex (M/F) 9/17 16/11 19/8 17/9 0.043
Age (years) 47.15 ± 13.91 44.96 ± 12.18 50.30 ± 13.09 46.00 ± 16.17 0.489
BMI (kg/m2) 24.79 ± 2.90 25.64 ± 3.89 27.74 ± 2.94▲▼ 28.58 ± 2.81▲▼ <0.001
Waist(cm) 84.86 ± 9.09 89.20 ± 9.60 94.43 ± 6.19▲▼ 99.02 ± 9.26▲▼ <0.001
WHR (cm/cm) 0.88 ± 0.08 0.92 ± 0.07▲ 0.95 ± 0.05▲ 0.95 ± 0.07▲ 0.001
SBP (mmHg) 121.12 ± 19.01 123.63 ± 13.69 132.63 ± 18.62▲ 138.88 ± 21.90▲▼ 0.002
DBP (mmHg) 75.88 ± 11.92 79.22 ± 10.08 81.96 ± 8.91▲ 88.81 ± 10.35▲▼◆ <0.001
TC (mmol/L) 4.78 ± 0.92 4.99 ± 0.87 4.91 ± 0.68 5.22 ± 0.86 0.308
TG (mmol/L) 1.62 ± 0.82 2.27 ± 1.31▲ 2.20 ± 1.26▲ 2.50 ± 1.31▲ 0.023
HDL-c (mmol/L) 1.30 ± 0.30 1.16 ± 0.24 1.08 ± 0.21▲ 1.10 ± 0.21▲ 0.009
LDL-c (mmol/L) 2.72 ± 0.73 2.99 ± 0.62 2.81 ± 0.58 3.04 ± 0.79 0.305
ALT (U/L)* 16.0(4.0-117.0) 28.0(11.0-124.0)▲ 38.0(12.0-121.0)▲ 63.0(11.0-259.0)▲▼◆ <0.001
AST (U/L)* 20.0(11.0-50.0) 23.0(11.0-78.0) 29.0(11.0-82.0)▲ 45.0(14.0-111.0)▲▼◆ <0.001
ALP (U/L) 64.22 ± 16.93 74.17 ± 17.55 76.21 ± 26.67 77.29 ± 18.96▲ 0.121
γ-GT (U/L)* 20.0(8–118.0) 32.5(15.0-139.0)▲ 38.5(17.0-112.0)▲ 67.0(16.0-378)▲▼◆ <0.001
VFA (cm2) 98.12 ± 32.84 105.21 ± 36.02 121.48 ± 35.74 134.14 ± 31.11▲▼ 0.040
SFA (cm2) 86.91 ± 22.81 76.51 ± 34.99 87.51 ± 27.61 109.88 ± 35.62▼ 0.032
VFA/SFA 1.15 ± 0.35 1.59 ± 0.77 1.62 ± 0.97 1.35 ± 0.52 0.374
Serum RBP4 (μg/ml) 43.23 ± 1.19 54.00 ± 8.74 51.75 ± 1.52 54.68 ± 8.86 0.298
Data are presented as means ± S.D or median (range).
*These variables were log transformed before analyses.
▲: compared with group Q1, P < 0.05; ▼: compared with group Q2, P < 0.05; ♦: compared with group Q3, P < 0.05.
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formed to determine the contributing factors to serum
RBP4 level. Independent variables were those indexes,
which were significantly associated with RBP4 in Pearson’s
correlation analysis in all subjects. We also performed
stepwise multiple linear regression analysis in different
gender, respectively. In all subjects, VFA (Standardized
Coefficients Beta = 0.357, p = 0.019) together with HDL-c
(Standardized Coefficients Beta = −0.345, p = 0.023) were
independent variables significantly associated with serum
RBP4. In women, VFA/SFA (Standardized Coefficients
Beta = 0.471, p = 0.049) was independently associated
with serum RBP4, while in men, HDL-c (Standardized
Coefficients Beta = −0.315, p = 0.040) was variable sig-
nificantly associated with serum RBP4 (Table 3).
RBP4 and hepatic fat content
The RBP4 concentrations were 43.23 ± 1.19 μg/ml, 54.00 ±
8.74 μg/ml, 51.75 ± 1.52 μg/ml and 54.68 ± 8.86 μg/ml
when HFC increased by quartile order, respectively. Al-
though the difference of RBP4 among the four groups was
not statistically significant, we found a phenomenon that
serum RBP4 level increased when HFC increased from Q1
to Q2, but, it did not increased anymore when HFC
increased from Q2 to Q4 (p = 0.298, Figure 1, Table 1). So,
we predicted that there might be a correlation betweenRBP4 and HFC when HFC was mildly elevated (less than
the median of 6.34%).
In light of the data mentioned above, we analyzed the
association between serum RBP4 concentration and
HFC in subjects within the first two quartiles of HFC and
all subjects, respectively (Figure 2). When HFC within Q1
to Q2 (less than 6.34%), there was a significant positive as-
sociation between RBP4 and HFC (r = 0.574, p = 0.001);
However, the association between HFC and RBP4 no
longer existed when HFC within Q3 to Q4 (more than
6.34%) (r = 0.097, p = 0.525).
Also, a stepwise multiple linear regression analysis was
performed in subjects whose HFC were less than 6.34%,
using HFC as a dependent variable, RBP4 as an inde-
pendent variable together with weight, BMI and waist
circumference, which are significantly associated with
hepatic fat content. And the results showed that RBP4
was significantly associated with HFC (Table 4), inde-
pendent of BMI, weight and waist circumference.
Discussion
To our knowledge, this is the first study to examine the
relationship between circulating RBP4 and body fat
composition, including hepatic fat content, visceral and
subcutaneous abdominal fat in a cohort of Chinese
NAFLD patients without known diabetes. And we find
Table 2 Univariate correlation of serum RBP4 in all the
subjects
Total (n = 106) Men (n = 61) Women (n = 45)
r P r P r P
Sex −0.415 <0.001
Age (y) 0.061 0.574 0.114 0.432 0.252 0.126
Weight (kg) 0.245 0.021 0.06 0.674 0.003 0.986
BMI (kg/m2) 0.048 0.653 0.034 0.814 −0.018 0.915
Waist (cm) 0.218 0.040 0.069 0.632 0.121 0.468
WHR 0.343 0.001 0.139 0.332 0.264 0.109
SBP (mmHg) 0.247 0.020 0.138 0.332 0.299 0.068
DBP (mmHg) 0.241 0.023 0.196 0.167 0.124 0.458
TC (mmol/L) 0.095 0.382 0.175 0.228 0.076 0.652
TG (mmol/L) 0.330 0.002 0.124 0.398 0.188 0.257
HDL-c (mmol/L) −0.392 <0.001 −0.298 0.045 −0.183 0.279
LDL-c (mmol/L) 0.049 0.658 0.108 0.476 0.113 0.504
ALT (U/L) 0.105 0.335 −0.287 0.048 0.168 0.312
AST (U/L) −0.077 0.487 −0.304 0.038 0.055 0.752
ALP (U/L) 0.116 0.310 −0.007 0.962 0.171 0.326
γ-GT (U/L) 0.239 0.034 0.142 0.357 0.042 0.810
SFA (cm2) −0.155 0.258 −0.093 0.584 −0.245 0.328
VFA (cm2) 0.298 0.027 0.207 0.218 0.271 0.277
VFA/SFA 0.289 0.032 0.163 0.335 0.470 0.049
HFC (%) 0.199 0.071 0.048 0.737 0.160 0.339
Data are means ± S.D, BMI: body-mass index, WHR: waist-to-hip ratio, TC: total
cholesterol, TG: triglyceride, HDL-c: high-density lipoprotein cholesterol, LDL-c:
low-density lipoprotein cholesterol, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, γ-GT: γ-glutamyltransferase, SFA: subcutaneous fat area, VFA:-
visceral fat area, HFC: hepatic fat content.
Figure 1 The association between serum RBP4 level and the
quartiles of hepatic fat content. When hepatic fat content increased
by quartile order, serum RBP4 level was 43.23 ± 1.19, 54.00 ± 8.74,
51.75 ± 1.52, 54.68 ± 8.86 μg/ml respectively. Serum RBP4 is not
proportionally increased with hepatic fat content (p = 0.298).
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visceral fat, but not hepatic fat content or subcutaneous
fat, which implied that visceral fat might be a major
source of excess circulating RBP4.
Consistent with our findings, relationship of RBP4 and
visceral fat was confirmed by many other studies in dif-
ferent populations [18,25-27], which suggest that visceral
obesity might play a key role in increasing the circulating
RBP4 level. Some intervention studies were conducted to
reduce weight of subjects by methods of bariatric surgeryTable 3 Multiple linear regression analysis of RBP4 and
Metabolic parameters
Standardized coefficients beta P value
ALL VFA 0.357 0.019
HDL-c −0.345 0.023
Men HDL-c −0.315 0.040
Women VFA/SFA 0.471 0.049
A step-wise multiple linear regression analysis was performed to determine
the contributing factors to serum RBP4 levels. Independent variables included
in multivariate regression model were variables whichwere significantly associated
with RBP4 in Pearson’s correlation analysis.or lifestyle modification and adjuvant appetite sup-
pressants, these results showed that circulating RBP4 level
decreased markedly, accompanied by reduction in visceral
fat mass [28,29]. The change in RBP4 level was signifi-
cantly correlated with the amount of abdominal visceral
fat loss but not associated with the amount of total body
fat loss or abdominal subcutaneous fat loss [29]. Mansouri
et al. found that exercise significantly reduced serum con-
centration of RBP4 in the trained diabetic rats, accompan-
ied by decreased RBP4 protein and gene expression in
visceral fat tissue. In contrast, exercise had no significant
effect on RBP4 protein and gene expression in liver in the
trained diabetic rats [30]. These studies confirmed the
relationship between RBP4 and visceral fat from the
reverse side.
Although some studies suggest that RBP4 associated
with HFC [9,19], we don’t find the relationship between
HFC and RBP4 in all the subjects. However, they are
significantly correlated when HFC is less than 6.34% (the
median of HFC). The disagreement with our findings
might be explained by the selection of patients with dif-
fering severity and duration of liver disease. Some studies
showed that RBP4 protein expression was down-regulated
in primary human adipocytes by TNF-α [31,32] and IL-1β
[32]. In NASH patients, a variety of inflammatory cyto-
kines rise gradually, exerting different influences on RBP4
expression, so the net concentration of circulating RBP4
can’t keep up with HFC. In addition, RBP4 is mainly se-
creted by liver, excessive fat deposition and severe lesion
in the liver may influence hepatic function, which prob-
ably lead to decreasing RBP4 secretion. Hence, we con-
clude that RBP4 may only reflect HFC on the early stage
of fatty liver, but not on the moderate-severe stage.
Figure 2 Pearson’s correlation analysis between serum RBP4 level
and hepatic fat content. Serum RBP4 level was positively correlated
with hepatic fat content when hepatic fat content is less than 6.34%
(r = 0.574, p = 0.001 Figure 2A). However, the association between
hepatic fat content and RBP4 no longer existed when hepatic fat
content more than 6.34% (r = 0.097, p = 0.525 Figure 2B) or all the
subjects (r = 0.199, p = 0.071 Figure 2C).
Table 4 Multiple linear regression analysis of RBP4 and
HFC (When HFC less than 6.34%)
Standardized coefficients beta P value
RBP4 0.395 0.014
Weight 0.311 0.049
A step-wise multiple linear regression analysis was performed to determine
the contributing factors to hepatic fat content. Independent variables included
weight, BMI, waist and RBP4.
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RBP4 was significantly lower than that in controls, in
contrast, RBP4 liver tissue expression was enhanced and
correlated with NAFLD histology [24]. RBP4 liver tissue
expression and circulating RBP4 level is not synchron-
ous might be another reason of inconsistent relationship
of HFC and RBP4.
No uniform diagnosis method might be another rea-
son for conflicting relationship between HFC and RBP4.
Those researches believing HFC and RBP4 were signifi-
cantly related used ultrasonic method to diagnose fatty
liver [9,19], while those researches getting different con-
clusions took liver biopsy to diagnose NAFLD and divided
them into different pathological changes [22,23,33]. And
they got a negative conclusion about relationship of RBP4
and nonalcoholic fatty liver disease, and RBP4 decreased
along with the deterioration of liver lesions [34].
The other reasons for that there is no relationship be-
tween HFC and RBP4 might because those studies
employed different study populations as well as various
laboratory assay methods and kits used to measure serum
RBP4. Graham et al. [35] found considerable discrepancy
among different assays measuring serum RBP4 in insulin-
resistant individuals. Quantitative western blotting is an
accurate assay method for measuring RBP4. In this study
serum RBP4 was detected by an enzyme immunoassay kit
and validated by quantitative Western blotting. So, the
data should be fairly accurate.
In the present work, VFA was associated with RBP4 in
women while HDL-c was negatively associated with
RBP4 in men, so there were gender discrepancy between
RBP4 and some metabolic parameters. Higher levels of
circulating RBP4 were discovered in men than in women
[17,36]. RBP4 level was different between premenopausal
and postmenopausal women and varied with pubertal
status [37]. These data suggest that sex hormones play
an important role in circulating RBP4 level, and this call
for further study.
There are several limitations in this study. Firstly, CT
scan is used to determine the hepatic fat content, and its
diagnostic accuracy is inferior to pathological diagnosis
by liver biopsy and 1H Magnetic Resonance Spectros-
copy (1H MRS). And we found the liver fat content de-
termined by CT was undervalued, hence, some patients
might not have NAFLD and still were included in this
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scan. So, the results come from this study could just be
considered as a clue, and the accurate relationships of
RBP4 and fat compartments needs further verification
by large scale studies and precise method of assessing
hepatic fat content, such as liver biopsy or 1H MRS. Sec-
ondly, our study is a cross-sectional study, which indi-
cate that cause and effect relationships between RBP4
and body fat composition can not be precisely determined.
Thirdly, RBP4 must be bound to retinol for efficient secre-
tion from hepatocytes, retinol deficiency reduces serum
RBP4. We do not determine retinol serum concentration
and therefore are not able to calculate the theoretic satur-
ation of RBP4 with retinol, which may affect the relation-
ship of RBP4 concentration and metabolic parameters.
In conclusion, RBP4 could be a marker of abdominal
obesity, but the role of RBP4 in the pathogenesis of
NAFLD is not sufficiently elucidated. These findings
should be validated with a larger cohort and more accur-




Eligible adults (age 18–70 years) were identified and
recruited from the outpatient department of Endocrin-
ology of Zhongshan hospital between Nov. 2005 and
Apr. 2006 who were diagnosed as fatty liver by ultra-
sound. Exclusion criteria were alcohol consumption re-
ported by themselves and their families of more than
30 g/d in the case of men and more than 20 g/d in the
case of women. Subjects were also excluded if they had
known diabetes, hepatitis B or C or other liver diseases,
or if they were receiving hypoglycemic or lipid-regulating
(statins, fibrates) drugs, or other drugs could impact hep-
atic fat content four weeks before the time of enrollment,
such as silybin, ursodeoxycholic acid, polyene, phosphat-
idylcholine, vitamin E, some Chinese herbs, etc. Other
exclusion factors were diseases affect the metabolic state
or other circumstance not suitable to participate in this
clinical trial. These details were described in our previous
article [36].
Anthropometric and biochemical measurements
Clinical data such as age, gender, height, weight were
collected. Body mass index (BMI) was calculated as the
weight in kilograms divided by the square of the height
in meters. Waist circumference was measured at the
midpoint between the inferior costal margin and the
superior border of the iliac crest on the midaxillary line.
Waist–hip ratio (WHR) was calculated as waist circumfer-
ence divided by hip circumference. Blood pressure was
measured three times with 5 minutes intervals each time
in the seated position with a mercury sphygmomanometerin the morning, and the average of the three blood pres-
sures was used as the final blood pressure.
Data on demographic variables, health status, health
behavior, and physical activity were collected using a
standardized questionnaire. All participants were required
to fast overnight (12 h) before physical examination by
trained staff and physicians using standard protocols.
Blood samples were drawn after an overnight fast and
immediately centrifuged. Serum glucose was measured
by the glucose oxidase method. Serum total cholesterol
(TC), triglycerides (TG), high-density lipoprotein chol-
esterol (HDL-c), low-density lipoprotein cholesterol
(LDL-c), and liver enzyme levels were determined by en-
zymatic methods with a Hitachi 7600 analyzer (Hitachi,
Ltd. Tokyo, Japan). Serum RBP4 (μg/ml) was measured in
duplicate by a sandwich ELISA developed in-house, using
affinity chromatography purified polyclonal and mono-
clonal antibodies generated against recombinant human
RBP4 protein. The assay system was subsequently cross
validated by Western blot analysis. The intra-assay
coefficient of variation was 1.8–7.6% and inter-assay
was 3.7–8.85% [36]. The study was approved by the
human research ethics committee of Zhongshan hospital,
Fudan University and informed consents were obtained
from all subjects.
Determination of hepatic fat content and body fat
distribution with calibrated CT
The abdominal adipose tissue areas were quantified by
CT scans using a Marconi MX8000 machine (Philips) by
the same one experienced doctor. With the subject in a
supine position, a 10-mm CT slice scan was acquired at
the L4 to L5 level to measure the total abdominal and
visceral fat area. Visceral fat area was quantified by
delineating the intra-abdominal cavity at the internal
aspect of the abdominal and oblique muscle walls
surrounding the cavity and the posterior aspect of the
vertebral body. The subcutaneous fat area (SFA) was
calculated by subtracting the visceral fat area from the
total abdominal fat area. Hepatic fat content was eval-
uated semi-quantitatively by CT scanning as previously
described [36].
Statistical analyses
All statistical analyses were performed using SPSS18.0
(SPSS Inc., Chicago, Illinois, USA). Normally distributed
data were expressed as means ± SD. Data that were not
normally distributed, as determined using Kolmogorox–
Smirnov test, were logarithmically transformed before
analysis and expressed as median with range. One-way
ANOVA was used for comparisons among groups, and
multiple testing was corrected using LSD method (Equal
Variances Assumed) or Games-Howell method (Equal
Varance not assumed). Pearson’s correlations and multiple
Chang et al. Lipids in Health and Disease  (2015) 14:28 Page 7 of 8stepwise regression analysis were used to examine the
association of serum RBP4, HFC, VFA, SFA and other
parameters. In all statistical tests, p values <0.05 were
considered significant.
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